Vaccination for whom? Time to reinvigorate Japanese vaccine policy

The Lancet

Volumn 380, Issue 9854, 2012, Pages 1647-

  Tanimoto, Tetsuya ^a   Murashige, Naoko ^b   Hosoda, Miwako ^c   Kusumi, Eiji ^a   Ono, Shunsuke ^b   Kami, Masahiro ^b   Shibuya, Kenji ^d  

^a Navitas Clinic   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Seisa University   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPLOID CELL VACCINE; ORAL POLIOMYELITIS VACCINE;

CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; GOVERNMENT; HUMAN; JAPANESE; LETTER; MEDICAL DECISION MAKING; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; VACCINATION; VIRUS STRAIN;

EID: 84868583387     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61948-5     Document Type: Letter

References (5)

1. Murashige N, Matsumura T, Kami M. Disseminating Japan's immunisation policy to the world. Lancet 2011; 377: 299.
2. Murashige N. Japan's immunization policy in routine, pandemic and post-tsunami situations. Int J Clin Pract 2011; 65: 1126-31.
3. Hosoda M, Inoue H, Miyazawa Y, Kusumi E, Shibuya K. Vaccine-associated paralytic poliomyelitis in Japan. Lancet 2012; 379: 520.
4. Fukue N. Polio shots sheds light on vaccine lag. Japan Times Jan 12, 2012. http://www. japantimes.co.jp/text/nn20120112f1.html (accessed Sept 1, 2012).
5. Liao G, Li R, Sun M, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase-II, randomized, positive-controlled trial. J Infec Dis 2012; 205: 237-43.